Leishmania–Host Cell Interaction and Immunopathogenesis
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Pathogens-host Immune Interface".
Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 4554
Special Issue Editors
Interests: immunology; vaccines; parasite-host interaction; miRNAs; immune metabolism
Interests: immunology; immunopathogenesis; parasite-host interaction; immunoparasitology
Interests: immunology; immunopathogenesis; molecular pathology
Special Issue Information
Dear Colleagues,
Parasite–host interaction is crucial for the development of infection, and depending on how the host immune response is activated, it will lead to the resolution or progression of the infection. Even with vast knowledge about host interaction that has been generated in recent years, there are still gaps in knowledge regarding how host–parasite interaction takes place and how pathogenic and immunological processes evolve in infection. It is essential to fill the knowledge gaps because an understanding of what happens in this interaction may lead to the discovery of mechanisms and/or molecules that can be used as biomarkers, immunoprophylactics, and for the development of vaccines.
This Special Issue of MPDI Vaccines focuses on the most recent progress trends in the Leishmania–host cell interaction and immunopathogenesis. We are pleased to invite you to contribute with an original research article, review, or perspective on the latest research to highlight (i) novel molecules candidates to be biomarkers, (ii) novel host/parasite molecules that act in pathological mechanisms candidates for new therapeutical approaches, (iii) immune responses elicited by immune therapy (new therapeutical approaches), and (iv) modulation of immune metabolism. This Special Issue will put emphasis on Leishmania infection in human and experimental studies.
We look forward to receiving your contributions.
Dr. Eduardo Milton Ramos-Sanchez
Dr. Luiza Campos Reis
Dr. Nidhi Sharma Dey
Dr. Fernando Real
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- leishmaniasis
- immune response
- pathogenesis
- biomarkers
- experimental model
- immunomodulators
